Cancer Drug Maker - Exelixis Inc

Despite years of research and millions and billions of investment, cancer is still one of the deadliest disease of the world.  And because it takes years to bring a cancer drug from discovery to market as it has to go through various stages of clinical trials and FDA (Food and Drug Administration) reviews, any positive progress during drug development always lift stock price of cancer drug maker.  


Therefore after reporting positive clinical trial data from patients receiving treatment for ovarian cancer and prostate cancer, shares of Exelixis Inc (EXEL) surged 32% to $6.23 per share.  The San Francisco based Exelixis develops compounds to fight various form of cancer including Brain, Breast, Endometrial, Ovarian, Gastric, Liver, Lung, Pancreatic, Prostate, Skinand Thyroid Cancer.  With such broad coverage, the company is on the forefront of cancer treatment drug development.  The multiple insider shares purchase since August were also great indication that positive things were about to happen to the drug maker.  In addition the company's financial situation continues to improve with increasing revenue and decreasing net loss.  This is definitely a stock worth looking at.